Reference Database

Activation of the Complement System in Patients with Cancer Cachexia.
Deng, Min
Vaes, Rianne D W
van Bijnen, Annemarie A J H M
Olde Damink, Steven W M
Rensen, Sander S
Cancers 2021 Nov 17;13(22): 5767

Systemic inflammation is thought to underlie many of the metabolic manifestations of cachexia in cancer patients. The complement system is an important component of innate immunity that has been shown to contribute to metabolic inflammation. We hypothesized that systemic inflammation in patients with cancer cachexia was associated with complement activation. Systemic C3a levels were higher in cachectic patients with inflammation ( = 23, C-reactive protein (CRP) ≥ 10 mg/L) as compared to patients without inflammation ( = 26, CRP < 10 mg/L) or without cachexia ( = 13) (medians 102.4 (IQR 89.4-158.0) vs. 81.4 (IQR 47.9-124.0) vs. 61.6 (IQR 46.8-86.8) ng/mL, respectively, = 0.0186). Accordingly, terminal complement complex (TCC) concentrations gradually increased in these patient groups (medians 2298 (IQR 2022-3058) vs. 1939 (IQR 1725-2311) vs. 1805 (IQR 1552-2569) mAU/mL, respectively, = 0.0511). C3a and TCC concentrations were strongly correlated (r = 0.468, = 0.0005). Although concentrations of C1q and mannose-binding lectin did not differ between groups, C1q levels were correlated with both C3a and TCC concentrations (r = 0.394, = 0.0042 and r = 0.300, = 0.0188, respectively). In conclusion, systemic inflammation in patients with cancer cachexia is associated with the activation of key effector complement factors. The correlations between C1q and C3a/TCC suggest that the classical complement pathway could play a role in complement activation in patients with pancreatic cancer.

Forward to a friend